Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0299053 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Masahiro Koizumi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Nephrologists, Nephrosis, Lipoid. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Background
In Japan, rituximab (RTX) for adult-onset frequently relapsing (FR)/steroid-dependent (SD) minimal change disease (MCD) is not explicitly reimbursed by insurance, and its standard regimen has not been established.
Methods
We conducted a cross-sectional web-based survey between November and December 2021. The participants were nephrologists certified by the Japanese Society of Nephrology and answered 7 items about RTX for adult MCD. Factors related to the experience of RTX administration at their facilities were estimated by generalized estimating equations.
Results
Of 380 respondents, 181 (47.6%) reported the experience of RTX use for adult MCD at their current facilities. Those who worked at university hospitals (vs. non-university hospitals, proportion difference 13.7%) and at facilities with frequent kidney biopsies (vs. 0 cases/year, 19.2% for 1–40 cases/year; 37.9% for 41–80 cases/year; 51.9% for ≥ 81 cases/year) used RTX more frequently. Of 181 respondents, 28 (15.5%) answered that there was no insurance coverage for RTX treatment. Of 327 respondents who had the opportunity to treat MCD, which was a possible indication for RTX, 178 (54.4%) indicated withholding of RTX administration. The most common reason was the cost due to lack of insurance coverage (141, 79.2%). Regarding RTX regimens for FR/SD MCD, introduction treatment with a single body surface area-based dose of 375 mg/m 2 and maintenance treatment with a 6-month interval were the most common.
Conclusion
This survey revealed the nephrologists’ characteristics associated with RTX use, the barriers to RTX use, and the variation in the regimens for adult MCD in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan.
- Department of Nephrology and Rheumatology, Aichi Medical University, Aichi, Japan.
- Section of Clinical Epidemiology, Department of Community Medicine, Kyoto University, Kyoto, Japan.
- Patient Driven Academic League (PeDAL), Tokyo, Japan.
- Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan.
- Section of Education for Clinical Research, Kyoto University Hospital, Kyoto, Japan.
ORCID-Profile: Masahiro Koizumi, Sayaka Shimizu, Sho Sasaki, Noriaki Kurita
Förderung
- Wellcome Trust
- Ministry of Health, Labour and Welfare
Zitieren
APA
Koizumi, M., Ishimoto, T., Shimizu, S., Sasaki, S., Kurita, N., & Wada, T. (2024). Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists. PLOS ONE. https://doi.org/10.1371/journal.pone.0299053
Vancouver
Koizumi M, Ishimoto T, Shimizu S, Sasaki S, Kurita N, Wada T. Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists. PLOS ONE. 2024. doi:10.1371/journal.pone.0299053
BibTeX
@article{Koizumi2024,
author = {Koizumi, Masahiro and Ishimoto, Takuji and Shimizu, Sayaka and Sasaki, Sho and Kurita, Noriaki and Wada, Takehiko},
title = {Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0299053}
}
EUVIMED